Thu, Jul 10, 2014, 10:30 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Ariad Pharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Nov 6, 2005 7:17 PM Flag

    Hey NEWHENEETOW, if Katagpa

    Mitosis03, as the following link explains, abstracts for research work will not be accepted for presentation automatically even though researchers all think that they have exciting new results to offer. Once submitted abstracts are accepted, they are simultaneously presented as posters which can be viewed at any time in a given session, or they are presented individually at particular times to audiences. While hundreds of posters are presented at any given time, only one verbal presentation can be run at a time in a given session (they must have general appeal, and many sessions are going at the same time). So, there are much fewer verbal presentations than posters. The selection committee decides which papers deserve verbal presentation.

    Also observe that this meeting is a special meeting for molecule-targeting drugs. Many oncologists are sold to the idea that the future of cancer cure depends on the targeted drugs such as Avastin, Tarceva, or AP23573.
    This new class of drugs targets signaling molecules such as mTOR, or EGFR, or VEGF rather than tumor cell DNA which traditional chemo drugs do. Above molecular targets are abundantly expressed in some tumor cells because tumor cell proliferation depends on the signals coming through these molecules to say: 'OK to divide'. As a result these drugs can be effective in killing tumor cells with less side effects than chemo or radiation which would harm all dividing cells. But some targeted drugs can inhibit more than one critical targets, one of which may be expressed well in normal tissue cells. These drugs have severe side effects as seen in Onxx-Bayer drug. However, combining targeted drugs may not have the same problem. Severity of side effects will determine efficacy of a drug. We'll have to watch for them with 573 PII reports and for glioma study to be presented as a poster. My assumption is that 573 PII result may not involve intolerable side effects, or have low response rate, if it did, the result would not be interesing enough to be presented in a meeting; there are other media.

    http://www.aacr.org/page4875.aspx

 
ARIA
5.95+0.03(+0.51%)Jul 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.